SynthesisThe Journal of urology2010
Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature.
Synthesis in The Journal of urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02315950 (CineMRI/UDS for Evaluating the Physiologic Effect of Botox in Women With Overactive Bladder), which is not on this map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CineMRI/UDS for Evaluating the Physiologic Effect of Botox in Women With Overactive Bladder
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- Pooled it
- Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis.Chinese medical journal · 2015Pooled it
- Outcomes of pregnancy following surgery for stress urinary incontinence: a systematic review.The Journal of urology · 2012Pooled it
- Low-energy extracorporeal shock-wave therapy with or without intravesical botulinum toxin A instillations for refractory interstitial cystitis/bladder pain syndrome: a randomized double-blind trial of clinical and biomarker outcomes.International urology and nephrology · 2026Trial
- Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB.International urogynecology journal · 2012Trial
- Comparison of Solifenacin and Bilateral Apical Fixation in the Treatment of Mixed and Urgency Urinary Incontinence in Women: URGE 1 Study, A Randomized Clinical Trial.In vivo (Athens, Greece)Trial
- Clinical and urodynamic indicators of non-response to OnabotulinumtoxinA in idiopathic overactive bladder.The Canadian journal of urology · 2026Article
- Review
- Diagnosis and management of urinary incontinence in females.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Review
- Nocturia: An overview of current evaluation and treatment strategies.World journal of methodology · 2025Review
- Six-Year Implants Follow-Up After Guided Bone Regeneration Using Autologous Tooth Graft: Innovative Biomaterial for Bone Regeneration Tooth TransformerJournal of functional biomaterials · 2025Article
- Advancements in the management of overactive bladder in women using nano-botulinum toxin type A: A narrative review.Current urology · 2025Review
- Article
- Intravesical botulinum toxin: Practice patterns from a survey of Canadian urologists.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- Functional Polymorphism in theJournal of clinical medicine · 2022Article
- Review
- Comparison of Two Treatment Modalities in Overactive Bladder: A Rapid Overview.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2022Review
- Review
- Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders-From Bench to Bedside.Toxins · 2020Review
- Assessment of Anticholinergic Use After Fading of BTX-A Effects in Refractory Idiopathic Overactive Bladder: A Prospective Blinded Randomized Trial.International neurourology journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
purposeWe systematically reviewed the evidence for the efficacy and safety of botulinum toxin in the management of overactive bladder. MATERIALS AND
methodsWe performed a systematic review of the literature to identify articles published between 1985 and March 2009 on intravesical botulinum toxin-A injections for the treatment of refractory idiopathic overactive bladder in men and women. Databases searched included MEDLINE, CENTRAL and Embase. Data were tabulated from case series and from randomized controlled trials, and data were pooled where appropriate.
resultsOur literature search identified 432 titles and 23 full articles were included in the final review. Three randomized placebo controlled trials addressing the use of botulinum toxin-A were identified (99 patients total). The pooled random effects estimate of effect across all 3 studies was 3.88 (95% CI -6.15, -1.62), meaning that patients treated with botulinum toxin-A had 3.88 fewer incontinence episodes per day. Urogenital Distress Inventory data revealed significant improvements in quality of life compared with placebo with a standardized mean difference of -0.62 (CI -1.04, -0.21). Data from case series demonstrated significant improvements in overactive bladder symptoms and quality of life, despite heterogeneity in methodology and case mix. However, based on the randomized controlled trials there was a 9-fold increased odds of increased post-void residual after botulinum toxin-A compared with placebo (8.55; 95% CI 3.22, 22.71).
conclusionsIntravesical injection of botulinum toxin resulted in improvement in medication refractory overactive bladder symptoms. However, the risk of increased post-void residual and symptomatic urinary retention was significant. Several questions remain concerning the optimal administration of botulinum toxin-A for the patient with overactive bladder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.